Detalhe da pesquisa
1.
Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.
Blood
; 142(3): 235-243, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37140031
2.
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.
Qual Life Res
; 29(7): 1903-1911, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32100182
3.
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity.
Clin Lymphoma Myeloma Leuk
; 23(6): 463-470.e1, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37076368
4.
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.
J Clin Oncol
; 40(30): 3489-3500, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36095296
5.
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.
Blood Adv
; 6(6): 1684-1691, 2022 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35114691
6.
Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data.
Blood Cancer J
; 12(4): 65, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35440047
7.
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
J Clin Oncol
; 40(8): 847-854, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34890212
8.
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement.
Blood Cancer J
; 11(8): 148, 2021 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465728
9.
Determination of Similarity Margin in Comparative Clinical Studies to Support the Development of Biosimilar Products of Neupogen® (Filgrastim, Granulocyte Colony-Stimulating Factor [G-CSF]).
BioDrugs
; 32(4): 325-330, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30006915
10.
FDA's Approval of the First Biosimilar to Bevacizumab.
Clin Cancer Res
; 24(18): 4365-4370, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743182
11.
Extreme body mass index and survival in newly diagnosed multiple myeloma patients.
Blood Cancer J
; 13(1): 13, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36631444
12.
Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study.
Clin Cancer Res
; 22(21): 5167-5170, 2016 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27582485
13.
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Clin Cancer Res
; 21(19): 4257-61, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26187614
14.
Evaluation of heart failure biomarker tests: a survey of statistical considerations.
J Cardiovasc Transl Res
; 6(4): 449-57, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23670231